全球Aminoglycosides市場規模、佔有率、趨勢及成長分析報告（2026-2034年）

預計Aminoglycosides市場將從 2025 年的 24.2 億美元成長到 2034 年的 35.7 億美元，2026 年至 2034 年的複合年成長率為 4.39%。

由於細菌感染和醫院感染疾病在全球持續蔓延，全球Aminoglycosides市場呈現穩定成長態勢。Aminoglycosides是一類對革蘭氏陰性菌有效的抗生素，在治療嚴重感染疾病方面繼續發揮至關重要的作用。敗血症、結核病和複雜性尿道感染率上升進一步推動了市場需求。此外，抗生素抗藥性的日益嚴重也使人們重新認知到Aminoglycosides抗生素作為臨床輔助聯合治療的重要性。

成長要素包括醫療基礎設施的擴張和新興經濟體住院人數的增加。政府推行的感染控制計畫和改善基本藥物取得途徑的政策也促進了市場擴張。製藥公司正加大研發投入，以改善藥物配方並降低毒性風險，而毒性歷來是限制藥物廣泛應用的主要因素。開發中國家對經濟有效且可靠的抗生素的需求不斷成長，也推動了市場的持續需求。

Aminoglycosides市場未來前景預計穩定，但成長較為溫和。藥物遞送系統的創新，例如呼吸道感染疾病的吸入療法，可能會開闢新的應用領域。然而，加強監管和合理的抗菌藥物使用方案可能會限制其濫用。持續進行旨在提高療效和減少副作用的新型Aminoglycosides衍生物的研究，預計將維持其在感染疾病治療中的重要性，從而有利於市場發展。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球Aminoglycosides市場：依產品分類

• 市場分析、洞察與預測
• 新黴素
• 妥布黴素
• 慶大霉素
• Amikacin
• Paromomycin
• 鏈黴素
• 其他產品

第5章 全球Aminoglycosides市場：依應用領域分類

• 市場分析、洞察與預測
• 細菌感染疾病
• 結核
• 其他用途

第6章：全球Aminoglycosides市場：依給藥途徑分類

• 市場分析、洞察與預測
• 注射藥物
• 口服
• 局部的
• 眼科

第7章 全球Aminoglycosides市場：依最終用途分類

• 市場分析、洞察與預測
• 醫院和診所
• 研究和學術機構
• 居家醫療環境
• 其他最終用戶

第8章 全球Aminoglycosides市場：按地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第9章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第10章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Aurobindo Pharma
  • Bausch Health Companies
  • Cipla
  • Fresenius Kabi
  • Kremoint Pharma（Bliss GVS Pharma）
  • Meiji Seika Pharma（Meiji Holdings）
  • Novartis
  • Perrigo Company
  • Pfizer
  • Sun Pharmaceutical Industries
  • Sanofi
  • Teva Pharmaceuticals

The Aminoglycosides Market size is expected to reach USD 3.57 Billion in 2034 from USD 2.42 Billion (2025) growing at a CAGR of 4.39% during 2026-2034.

The Global Aminoglycosides Market has experienced steady growth due to the persistent prevalence of bacterial infections and hospital-acquired infections worldwide. Aminoglycosides, a class of antibiotics effective against Gram-negative bacteria, remain critical in severe infection management. Increasing incidences of sepsis, tuberculosis, and complicated urinary tract infections have sustained demand. Additionally, the rise in antimicrobial resistance has reinforced the importance of combination antibiotic therapies where aminoglycosides are often used as adjunct treatments in clinical practice.

Key growth drivers include expanding healthcare infrastructure in emerging economies and increased hospital admissions. Government initiatives promoting infection control programs and greater access to essential medicines also support market expansion. Pharmaceutical companies are investing in research to improve drug formulations and reduce toxicity concerns, which historically limited broader usage. The growing need for cost-effective and reliable antibiotics in developing countries further contributes to sustained demand.

Future prospects for the aminoglycosides market appear stable, though moderate in growth rate. Innovation in drug delivery systems, such as inhalation therapies for respiratory infections, could unlock new application areas. However, regulatory scrutiny and antimicrobial stewardship programs may restrict overuse. The market is expected to benefit from ongoing research into novel aminoglycoside derivatives with enhanced efficacy and reduced side effects, ensuring continued relevance in infectious disease treatment.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product

• Neomycin
• Tobramycin
• Gentamicin
• Amikacin
• Paromomycin
• Streptomycin
• Other Products

By Application

• Bacterial Infection
• Tuberculosis
• Other Applications

By Route Of Administration

• Injectable
• Oral
• Topical
• Ophthalmic

By End Use

• Hospitals And Clinics
• Research And Academic Institutes
• Homecare Settings
• Other End Users

COMPANIES PROFILED

• Aurobindo Pharma, Bausch Health Companies, Cipla, Fresenius Kabi, Kremoint Pharma Bliss GVS Pharma, Meiji Seika Pharma Meiji Holdings, Novartis, Perrigo Company, Pfizer, Sun Pharmaceutical Industries, Sanofi, Teva Pharmaceuticals

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL AMINOGLYCOSIDES MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. Neomycin Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Tobramycin Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Gentamicin Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Amikacin Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Paromomycin Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Streptomycin Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.8. Other Products Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL AMINOGLYCOSIDES MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Bacterial Infection Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Tuberculosis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Other Applications Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL AMINOGLYCOSIDES MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Route Of Administration
• 6.2. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Topical Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Ophthalmic Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL AMINOGLYCOSIDES MARKET: BY END USE 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast End Use
• 7.2. Hospitals And Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Research And Academic Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Homecare Settings Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Other End Users Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL AMINOGLYCOSIDES MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Product
  • 8.2.2 By Application
  • 8.2.3 By Route Of Administration
  • 8.2.4 By End Use
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Product
  • 8.3.2 By Application
  • 8.3.3 By Route Of Administration
  • 8.3.4 By End Use
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Product
  • 8.4.2 By Application
  • 8.4.3 By Route Of Administration
  • 8.4.4 By End Use
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Product
  • 8.5.2 By Application
  • 8.5.3 By Route Of Administration
  • 8.5.4 By End Use
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Product
  • 8.6.2 By Application
  • 8.6.3 By Route Of Administration
  • 8.6.4 By End Use
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL AMINOGLYCOSIDES INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Aurobindo Pharma
  • 10.2.2 Bausch Health Companies
  • 10.2.3 Cipla
  • 10.2.4 Fresenius Kabi
  • 10.2.5 Kremoint Pharma (Bliss GVS Pharma)
  • 10.2.6 Meiji Seika Pharma (Meiji Holdings)
  • 10.2.7 Novartis
  • 10.2.8 Perrigo Company
  • 10.2.9 Pfizer
  • 10.2.10 Sun Pharmaceutical Industries
  • 10.2.11 Sanofi
  • 10.2.12 Teva Pharmaceuticals